Expiration date: 01/2027

Finasteride-Teva

Release form

Tablet, coated

Composition

1 tablet coated liner contains finasteride 5 mg.

Packaging

30 or 90 PCs.

Pharmacological action

Finasteride-synthetic 4-azasteroid connection, a competitive and specific inhibitor of steroid 5-alpha-reductase inhibitors - intracellular enzyme, which converts testosterone to the active androgen 5-dihydrotestosterone. The growth of the prostate tissue and the development of benign hyperplasia due to the conversion of testosterone to dihydrotestosterone in the prostate cells. The drug is a significant reduction in the concentration of digidrosteron as in plasma and in prostate tissue. Finasteride does not bind to androgen receptors. The result of the drug reduces prostate size, decreases symptoms associated with benign prostatic hyperplasia. The drug has no effect on the plasma lipid concentration and content in plasma cortisol, estradiol, prolactin, thyroid-stimulating hormone, thyroxine.

Testimony

Finasteride-Teva is indicated for benign prostatic hyperplasia (to reduce prostate size, increase in maximum urine flow and reduce symptoms associated with hyperplasia, reduce the risk of acute urinary retention and the consequent likelihood of surgery. 

Contraindications

Hypersensitivity to finasteride and other ingredients components of the drug, prostate cancer, urinary tract obstruction, childhood.

Caution - the liver.

Method of application and doses

Finasteride-Teva is taken orally regardless of the meal, 1 tablet (5mg) a day for 6-7 months.

Special instructions

Before treatment is necessary to exclude diseases that can simulate the benign prostatic hyperplasia, such as infectious prostatitis, prostate cancer, stricture of the urethra, hypotension bladder and a number of changes in the urinary system, emerging in certain diseases of the nervous system. Because when you apply finasteride decrease prostate-specific antigen (on 41% and 48% respectively for 6 and 12 months from start of therapy), periodically during therapy to investigate patients to exclude them from prostate cancer. Women of childbearing age and pregnant women should avoid contact with crushed Finasteride tablets, because the ability of the drug to inhibit the transformation of testosterone into dihydrotestosterone can cause impaired development of the genital organs in male fetus. Finasteride tablets are film-coated and at normal treatment, if they are not powdered or n violated their integrity, contact with the active material removed.

Storage conditions

In a dry, light protected and inaccessible to children place at temperature not exceeding 25C°